SUPERNUS PHARMACEUTICALS, INC.(SUPN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

SUPERNUS PHARMACEUTICALS, INC. (SUPN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SUPN at 41.9/100 on a 32-signal composite quality model, placing it at rank #2,042 of 2,960 stocks — the bottom half of the AI-ranked universe. SUPN scores in the top quartile across revenue growth (76.4). Areas of concern include profitability (16.6) and balance sheet strength (19.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SUPERNUS PHARMACEUTICALS, INC. reports quarterly revenue of $219.1M, net income of $-58.4M, free cash flow of $-5.4M. Top institutional holders of SUPN by reported 13-F value include BlackRock, MILLENNIUM MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. SUPN trades on the Nasdaq exchange and files with the SEC under CIK 1356576. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SUPN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUPERNUS PHARMACEUTICALS, INC. directly from SEC EDGAR.